Introducing Empagliflozin Tablets by PharmAlliance International Labs

At PharmAlliance International Labs, we are dedicated to revolutionizing diabetes management with our innovative pharmaceutical solutions. Our Empagliflozin Tablets offer a cutting-edge approach to managing type 2 diabetes mellitus, providing patients with a reliable treatment option to control blood sugar levels and reduce the risk of cardiovascular events.

Drug Classification: Redefining Diabetes Treatment with SGLT2 Inhibitors

Empagliflozin belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. This groundbreaking drug class operates by inhibiting the reabsorption of glucose in the kidneys, thereby promoting the excretion of excess glucose in the urine and effectively lowering blood sugar levels. By targeting glucose reabsorption mechanisms, Empagliflozin offers a unique and powerful approach to diabetes management, addressing the underlying pathophysiology of the disease.

Formulations: Precision Formulation for Enhanced Efficacy

Our Empagliflozin Tablets are formulated to deliver optimal therapeutic outcomes with convenience and reliability:

Strength: Available in a formulation containing Empagliflozin 10mg.

Product Form: Oral tablets for convenient administration.

Packing Specifications: Packaged in blister packs containing 30 tablets each, ensuring easy storage and accessibility throughout the treatment regimen.

Indications: Comprehensive Treatment for Diabetes and Cardiovascular Health

Empagliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Beyond glycemic management, Empagliflozin has demonstrated significant benefits in reducing the risk of cardiovascular death and hospitalization for heart failure in patients with established cardiovascular disease. This comprehensive approach to diabetes care underscores the multifaceted impact of Empagliflozin on both metabolic and cardiovascular health.

Usage: Optimizing Treatment Adherence and Monitoring:

For optimal therapeutic efficacy, Empagliflozin Tablets should be taken orally once daily, with or without food. Adherence to the prescribed dosage and regimen outlined by healthcare providers is essential to maximize treatment benefits. Regular monitoring of blood glucose levels and kidney function is recommended to assess treatment response and ensure patient safety throughout the course of therapy.

Dosage: Personalized Approach to Diabetes Management:

The recommended dosage of Empagliflozin Tablets is 10 mg once daily. Dose adjustment may be necessary based on individual patient factors such as renal function and tolerability. Empagliflozin can be used as monotherapy or in combination with other antidiabetic medications, providing flexibility and personalized treatment approaches to meet the unique needs of each patient.

Pharmacokinetics and Pharmacodynamics: Insights into Mechanisms of Action:

Empagliflozin exhibits rapid absorption following oral administration, with peak plasma concentrations achieved within 1.5 hours. Metabolized primarily in the liver, Empagliflozin undergoes renal excretion of metabolites, with an elimination half-life of approximately 12.4 hours. Pharmacodynamically, Empagliflozin acts by inhibiting the SGLT2 transporter in the proximal renal tubules, leading to increased urinary glucose excretion and reduced blood glucose levels independently of insulin secretion or action.

Side Effects: Prioritizing Patient Safety and Well-Being:

While generally well-tolerated, Empagliflozin Tablets may elicit common side effects such as urinary tract infections, genital yeast infections, and increased urination. Patients should be aware of the potential risk of hypoglycemia, especially when Empagliflozin is used in combination with insulin or insulin secretagogues. Any persistent or severe side effects should be promptly reported to healthcare providers for appropriate management and guidance.

Experience the benefits of Empagliflozin Tablets from PharmAlliance International Labs. Trust in our unwavering commitment to delivering high-quality medications that support the management of type 2 diabetes mellitus and improve cardiovascular outcomes. For more information, please visit our website or consult your healthcare provider.


There are no reviews yet.

Be the first to review “Empagliflozin”

Your email address will not be published. Required fields are marked *

Pharmalliance.pkĀ© 2024. All rights reserved. Terms of use and Privacy Policy